Caribou Biosciences, Inc. Reports Material Event through SEC Filing

Strategic Insights -

Caribou Biosciences, Inc., a biotechnology company, has reported a material event through a U.S. Securities and Exchange Commission (SEC) filing. The filing, submitted on March 9, 2023, reveals a significant occurrence that affects investors or security holders. This event is detailed in a "current report" submitted using Form 8-K, which is used to report the occurrence of any material events or corporate changes that were previously unknown to investors.

Key Takeaways:

  • Caribou Biosciences, Inc. has submitted a Form 8-K SEC filing to report a material event.
  • The SEC filing was submitted on March 9, 2023, and involves significant corporate changes or events.
  • The filing contains 14 documents, with the SEC file number 0001619856-23-000035.
  • The contact information for Caribou Biosciences, Inc. is 2929 7th Street, Suite 105, Berkeley, CA 94710, with a phone number of 510-982-6030.
  • The SEC filing provides current information on material events not previously reported by the company.
  • This filing implies that investors and security holders should be aware of the changes or events reported by Caribou Biosciences, Inc.

Statistics:

  • The SEC filing was submitted on March 9, 2023.
  • The filing contains 14 documents.
  • The SEC file number is 0001619856-23-000035.
  • Caribou Biosciences, Inc. is a biotechnology company (SIC code 2836, Biological Products).
  • The company's address is 2929 7th Street, Suite 105, Berkeley, CA 94710, with a phone number of 510-982-6030.
  • The company has not provided a specific date or timeframe for the occurrence of the material event.

Sources:

  • "U.S. Securities and Exchange Commission." (SEC filing) Form 8-K filed by Caribou Biosciences, Inc. March 9, 2023.
  • "National Institute of Standards and Technology." (U.S. Securities and Exchange Commission filing) What are Form 8-K and Form 10-K? Retrieved 2023, March 28.